Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047565 · ClinicalTrials.gov registry record · Phase 1
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT02047565 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 110 participants.
The verdict
NCT02047565, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
This Phase 1 study consists of 2 parts. Part 1 will be an open-label, randomized, 2 treatment, 2-way crossover study. Part 2 will be a double-blind (Sponsor unblinded), randomized, placebo controlled, sequential descending prothrombin complex concentrate dose, 2 sequence, 2 period crossover study. In both parts of the study, the assessor of BD and BV will remain blinded. In Part 2 of the study, both the subject and the clinic staff involved in study conduct will be blinded (with the exception of the pharmacist or nurse who prepares the blinded individual treatments from open-label supplies). The study programmer and statistician will also be blinded to treatment assignment. The Sponsor will remain unblinded for both parts of the study.
Interventions
- DRUG 60mg edoxaban
- DRUG 180mg edoxaban
- DRUG 50 IU/kg Beriplex P/N
- DRUG 25 IU/kg Beriplex P/N
- DRUG 10 IU/kg Beriplex P/N
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047565
The ClinicalTrials.gov registry entry for NCT02047565 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 60mg edoxaban is the first listed.
NCT02047565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02047565 about?
NCT02047565 is a clinical study titled "A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation". This Phase 1 study consists of 2 parts. Part 1 will be an open-label, randomized, 2 treatment, 2-way crossover study. Part 2 will be a double-blind (Sponsor unblinded), randomized, placebo controlled, sequential descending prothrombin complex concentrate dose, 2 sequence, 2 period crossover study. I...
What is the current status of trial NCT02047565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2013-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02047565?
The interventions under investigation include: 60mg edoxaban (DRUG), 180mg edoxaban (DRUG), 50 IU/kg Beriplex P/N (DRUG), 25 IU/kg Beriplex P/N (DRUG), 10 IU/kg Beriplex P/N (DRUG).
Who is sponsoring clinical trial NCT02047565?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.